Apyx Medical Corporation (APYX)

Apyx Medical's stock has experienced significant events driven by financial performance and product developments. As of May 1, 2026, the share price was $3.06, a 166.09% increase from May 5, 2025. In Q4 2025, Apyx Medical reported record revenue of $19.2 million, with full-year revenue at $52.8 million, driven by the AYON Body Contouring System launch. The company narrowed its net loss to $11.2 million for 2025 and provided a revenue forecast for 2026. In Q1 2026, revenue was $12.5 million, a 32% increase, driven by the Surgical Aesthetics segment, and the net loss narrowed. Apyx Medical raised its FY2026 revenue guidance, and the stock price increased after the Q1 2026 earnings announcement. The anticipated FDA clearance for AYON power liposuction is a future growth catalyst.

The medical device industry typically experiences seasonality, with revenue lowest in the first and third quarters and strongest in the second and fourth quarters. This is attributed to factors like summer vacations and year-end spending. Apyx Medical's Q1 2026 earnings call mentioned this seasonality, with domestic revenue increasing 20% and international revenue increasing 63%. The company's guidance acknowledges this typical seasonality in the aesthetic space.

Apyx Medical Corporation is an energy technology medical device company focused on cosmetic and surgical products. They operate in the Healthcare sector, specifically the Medical Devices industry, with two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Their core products include Renuvion, J-Plasma, and the AYON Body Contouring System, which received FDA 510(k) clearance in May 2025 and launched commercially in September 2025. The company anticipates FDA clearance for AYON power liposuction in mid-2026. Apyx Medical also leverages its waveform technology through OEM agreements.

Apyx Medical Corporation is based in Clearwater, Florida, and has a wholly-owned limited liability company, Apyx Bulgaria, EOOD, in Sofia, Bulgaria. Apyx Bulgaria is involved in development, manufacturing, distribution, and service activities. The company has expanded internationally, gaining regulatory approval in Australia, Brazil, Israel, Taiwan, and Thailand in June 2020, and in South Korea in December 2025. Their commercial strategy focuses on Renuvion in cosmetic surgery and J-Plasma in the hospital surgical market.

Apyx Medical has received positive recognition for its products, including Renuvion winning the 2026 NewBeauty Award for "Best Minimally Invasive Skin Tightener." The company is focusing on direct-to-consumer marketing programs for the Renuvion system, generating significant reach and positive public relations. The successful commercial launch and strong demand for the AYON Body Contouring System also contribute positively to the company's reputation.

Apyx Medical Corporation has 55 institutional owners and shareholders holding 18,861,080 shares. Major institutional owners include Nantahala Capital Management, LLC, Archon Capital Management LLC, and Royce & Associates Lp. As of January 2026, institutional investors decreased their holdings slightly, while mutual funds increased their holdings. Insiders' holdings remained unchanged. The CEO, Charles Goodwin, directly owns 0.22% of the company's shares, and Senior Vice President Moshe Citronowicz directly owns 493,504 shares.